FRI0213 Comparative Effectiveness of Abatacept, Rituximab, Tocilizumab and Anti-TNF Biological Dmards in Ra: Results From the Nationwide Swedish Register

doi 10.1136/annrheumdis-2017-eular.1307
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ Publishing Group Ltd and European League Against Rheumatism

Related search

Cost-Effectiveness of Abatacept, Tocilizumab and TNF-inhibitors Compared With Rituximab as Second-Line Biologic Drug in Rheumatoid Arthritis

PLoS ONE
Multidisciplinary
2019English

Tocilizumab: Is There Life Beyond Anti-TNF Blockade?

International Journal of Clinical Practice
Medicine
2011English

AB0396 Tocilizumab i.v. Effectiveness in Ra Patients Is Independent of Smoking Status

2017English

SP0065 to Taper or Not to Taper Non Biological Dmards in Ra Remission?

2018English

Co1 Comparative Effectiveness Analysis of TNF Blockers in Rheumatoid Arthritis (Ra) Patients in a Real-World Setting

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2011English

THU0725-HPR Cost Effectiveness Analysis of Abatacept Compared With TNF Inhibitors in Patients Who Are Positive for Anti-Citrullinated Protein Antibodies Based on Results From an Observational Trial

2017English

Ultrasonographic Efficacy of Biologic and Targeted Synthetic DMARDs Therapy in RA From Multicenter RA Ultrasound Prospective Cohort in Japan

Arthritis Care and Research
Rheumatology
2018English

SAT0206 Retention of Tocilizumab as Monotherapy Versus TNF Inhibitors With Conventional Synthetic Dmards in Rheumatoid Arthritis Patients With Inadequate Response to TNF Inhibitors: A Study From the Tocerra Collaboration

2017English

Expressions of Circadian Clock Genes Represent Disease Activities of RA Patients Treated With Biological DMARDs

Modern Rheumatology
MedicineRheumatology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy